For decades, epilepsy treatment has focused on stopping seizures, but for the third of patients whose seizures resist existing medicines, that approach is not enough. As genetics, neural circuits, and cell therapies reshape the field, epilepsy is being redefined as many diseases with deeper biological roots.
Molecular surgery: How Europe can lead the world
Latest News, OpinionKJ Muldoon’s survival was not just a medical breakthrough. It was a glimpse of a new category of medicine, in which a genetic error can be corrected with the precision of an operation rather than developed as a conventional drug. Can Europe build the system that turns one extraordinary rescue into a repeatable model?
BioNTech cancer vaccine trial halted after survival imbalance
Latest NewsBioNTech and Genentech have terminated a Phase 2 trial of their personalized mRNA cancer vaccine autogene cevumeran in colorectal cancer after more deaths occurred in the vaccine arm than among patients under observation. The setback comes just days after rival Moderna scored the first Phase 3 success for an individualized mRNA cancer therapy — albeit in combination with a checkpoint inhibitor.
Heidelberg Pharma deepens ADC alliance with Huadong
Latest NewsGerman biotech Heidelberg Pharma and China-based Huadong Medicine are drawing ever closer: What began as a licensing partnership has developed into an alliance spanning capital investment, joint ADC development and clinical research. Now, up to six new targets are being added, making the partnership increasingly strategic.
Revealis enters cancer vaccine race with TEIPP strategy
Latest NewsDutch startup Revealis Biotherapeutics has launched to develop a new generation of cancer vaccines targeting tumor cells that have become difficult for T cells to recognize, building on an academic program that has already reached patients.
Osivax and GC Biopharma partner on broader flu vaccine
Latest NewsFrench biotech Osivax and South Korea-based GC Biopharma have partnered to develop a seasonal influenza vaccine combining Osivax’s broad-spectrum OVX836 candidate with GC Biopharma’s marketed GC FLU vaccine.
Redx raises $36M to fund Phase 2 Crohn’s disease trial
Latest NewsUK-based Redx Pharma has closed a $36 million (€31 million) Series A financing round to support a Phase 2 trial of its Crohn’s disease drug candidate.
Berlin-developed Ebola vaccine heads toward African trial
Latest NewsThe Coalition for Epidemic Preparedness Innovations (CEPI) is providing Egyptian biopharmaceutical company Minapharm with up to $16.5 million (€14 million) to advance another vaccine candidate against Bundibugyo Ebola virus into clinical development. The candidate was developed by Minapharm’s Berlin-based subsidiary ProBioGen using its proprietary MVA-CR19 platform. A Phase I trial is planned in Africa, with the broader aim of helping the continent build the capacity to respond rapidly to emerging outbreaks.
How biotech is treating epilepsy beyond seizures
Background, Latest NewsFor decades, epilepsy treatment has focused on stopping seizures, but for the third of patients whose seizures resist existing medicines, that approach is not enough. As genetics, neural circuits, and cell therapies reshape the field, epilepsy is being redefined as many diseases with deeper biological roots.
Samanta Cimitan to (re)join Lonza from Celonic
AppointmentsSamanta Cimitan will join Lonza as Chief Commercial Officer (CCO), Senior Vice President and a member of the Extended Executive Committee on 1 January 2027. In the newly created role, she will lead Strategic Enterprise Account Management, Global Marketing and Commercial Excellence. She´s been with Lonza before her CEO role at Celonic for the last three years.
Apollo vaccine triggers broad rhinovirus immunity in Phase 1
Latest NewsUK biotech Apollo Therapeutics has reported early Phase 1 data showing that one dose of its experimental rhinovirus vaccine, APL-10456, induced immune responses recognizing all three rhinovirus species in healthy adults.